Estimation of P-glycoprotein-mediated efflux in the oral absorption of P-gp substrate drugs from simultaneous analysis of drug dissolution and permeation

European Journal of Pharmaceutical Sciences

Volumn 44, Issue 4, 2011, Pages 544-551

  Kataoka, Makoto ^a   Yokoyama, Tomonori ^a   Masaoka, Yoshie ^a   Sakuma, Shinji ^a   Yamashita, Shinji ^a  

^a SETSUNAN UNIVERSITY   (Japan)

Author keywords

Cremophor EL; Drug drug interaction; In vitro in vivo correlation; Oral absorption; P glycoprotein

Indexed keywords

CREMOPHOR; ERYTHROMYCIN; FEXOFENADINE; GLYCOPROTEIN P; LOPERAMIDE; QUINIDINE; SAQUINAVIR; TALINOLOL; VERAPAMIL; VINBLASTINE;

APICAL MEMBRANE; AREA UNDER THE CURVE; ARTICLE; BASEMENT MEMBRANE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOLAYER CULTURE; ORAL DRUG ADMINISTRATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT;

ALGORITHMS; CACO-2 CELLS; DRUG INTERACTIONS; ERYTHROMYCIN; GENE EXPRESSION; GLYCEROL; HUMANS; INTESTINAL ABSORPTION; LOPERAMIDE; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; PROPANOLAMINES; PUROMYCIN; QUINIDINE; SAQUINAVIR; SOLUBILITY; SURFACE-ACTIVE AGENTS; TERFENADINE; VERAPAMIL; VINBLASTINE;

EID: 80455122645     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2011.09.007     Document Type: Article

References (36)

1. S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ramachandra, I. Pastan, and M.M. Gottesman Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu. Rev. Pharmacol. Toxicol. 39 1999 361 398 (Pubitemid 29222564)
2. L.Z. Benet, T. Izumi, Y. Zhang, J.A. Silverman, and V.J. Wacher Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery J. Controlled Release 62 1999 25 31 (Pubitemid 29486478)
3. M.B. Bolger, V. Lukacova, and W.S. Woltosz Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine AAPS J. 11 2009 353 363
4. X. Cao, L.X. Yu, C. Barbaciru, C.P. Landowski, H.C. Shin, S. Gibbs, H.A. Miller, G.L. Amidon, and D. Sun Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability Mol. Pharm. 2 2005 329 340 (Pubitemid 41186409)
5. G. Cornaire, J.F. Woodley, S. Saivin, J.Y. Legendre, S. Decourt, A. Cloarec, and G. Houin Effect of polyoxyl 35 castor oil and polysorbate 80 on the intestinal absorption of digoxin in vitro Arzneim.-Forsch. 50 2000 576 579 (Pubitemid 30418417)
6. B. Davies, and T. Morris Physiological parameters in laboratory animals and humans Pharm. Res. 10 1993 1093 1095 (Pubitemid 23211439)
7. I.A. de Lannoy, and M. Silverman The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin Biochem. Biophys. Res. Commun. 189 1992 551 557 (Pubitemid 23030076)
8. Y.M. Di, C.G. Li, C.C. Xue, and S.F. Zhou Clinical drugs that interact with St. John's wort and implication in drug development Curr. Pharm. Des. 14 2008 1723 1742 (Pubitemid 351998596)
9. W. Doering Quinidine-digoxin interaction: pharmacokinetics, underlying mechanism and clinical implications N. Engl. J. Med. 301 1979 400 404 (Pubitemid 9248654)
10. G.K. Dresser, R.B. Kim, and D.G. Bailey Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides Clin. Pharmacol. Ther. 77 2005 170 177 (Pubitemid 40269132)
11. E. Galia, E. Nicolaides, D. Hörter, R. Löbenberg, C. Reppas, and J.B. Dressman Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs Pharm. Res. 5 1998 698 705 (Pubitemid 28275645)
12. L.S. Gan, M.A. Moseley, B. Khosla, P.F. Augustijns, T.P. Bradshaw, R.W. Hendren, and D.R. Thakker CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells Drug. Metab. Dispos. 24 1996 344 349
13. T. Giessmann, K. May, C. Modess, D. Wegner, U. Hecker, M. Zschiesche, P. Dazert, M. Grube, E. Schroeder, R. Warzok, I. Cascorbi, H.K. Kroemer, and W. Siegmund Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans Clin. Pharmacol. Ther. 76 2004 192 200 (Pubitemid 39221793)
14. B. Greiner, M. Eichelbaum, P. Fritz, H.P. Kreichgauer, O. von Richter, J. Zundler, and H.K. Kroemer The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin J. Clin. Invest. 104 1999 147 153
15. Guidance for Industry, 2006. Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling (DRAFT GUIDANCE). .
16. B.J. Gurley, A. Swain, D.K. Williams, G. Barone, and S.K. Battu Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics Mol. Nutr. Food Res. 52 2008 772 779
17. S. Igel, S. Drescher, T. Murdter, U. Hofmann, G. Heinkele, H. Tegude, H. Glaeser, S.S. Brenner, A.A. Somogyi, T. Omari, C. Schafer, M. Eichelbaum, and M.F. Fromm Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux Clin. Pharmacokinet. 46 2007 777 785 (Pubitemid 47347449)
18. M. Kataoka, Y. Masaoka, Y. Yamazaki, T. Sakane, H. Sezaki, and S. Yamashita In vitro system to evaluate oral absorption of poorly water-soluble drugs: simultaneous analysis on dissolution and permeation of drugs Pharm. Res. 20 2003 1674 1680 (Pubitemid 37268286)
19. M. Kataoka, Y. Masaoka, S. Sakuma, and S. Yamashita Effect of food intake on the oral absorption of poorly water-soluble drugs: in vitro assessment of drug dissolution and permeation assay system J. Pharm. Sci. 95 2006 2051 2061 (Pubitemid 44433034)
20. K.A. Kim, J. Chung, D.H. Jung, and J.Y. Park Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes Eur. J. Clin. Pharmacol. 60 2004 575 581 (Pubitemid 39517911)
21. M. Martin-Facklam, J. Burhenne, R. Ding, R. Fricker, G. Mikus, I. Walter-Sack, and W.E. Haefeli Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL Br. J. Clin. Pharmacol. 53 2002 576 581 (Pubitemid 34621782)
22. K. Morimoto, M. Nakakariya, Y. Shirasaka, C. Kakinuma, T. Fujita, I. Tamai, and T. Ogihara Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein Drug. Metab. Dispos. 36 2008 6 9
23. H.R. Ochs, D.J. Greenblatt, and E. Woo Clinical pharmacokinetics of quinidine Clin. Pharmacokinet. 5 1980 150 168 (Pubitemid 11248747)
24. A.J. Sadeque, C. Wandel, H. He, S. Shah, and A.J. Wood Increased drug delivery to the brain by P-glycoprotein inhibition Clin. Pharmacol. Ther. 68 2000 231 237
25. U.I. Schwarz, T. Gramatté, J. Krappweis, R. Oertel, and W. Kirch P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans Int. J. Clin. Pharmacol. Ther. 38 2000 161 167 (Pubitemid 30193611)
26. Y. Shirasaka, M. Kawasaki, T. Sakane, H. Omatsu, Y. Moriya, T. Nakamura, T. Sakaeda, K. Okumura, P. Langguth, and S. Yamashita Induction of human P-glycoprotein in Caco-2 cells: development of a highly sensitive assay system for P-glycoprotein-mediated drug transport Drug. Metab. Pharmacokinet. 21 2006 414 423
27. Y. Shirasaka, T. Sakane, and S. Yamashita Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane J. Pharm. Sci. 97 2008 553 565
28. M.D. Troutman, and D.R. Thakker Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium Pharm. Res. 20 2003 1210 1224 (Pubitemid 36951846)
29. A. Urae, M. Okada, R. Kimura, K. Matsukuma, H. Furuie, H. Tsukikawa, Y. Nitta, M. Nishikawa, and S. Irie Clinical pharmacology study of drug interaction between fexofenadine hydrochloride and erythromycin: electrocardiographic findings and pharmacokinetics of concomitant administration of fexofenadine hydrochloride and erythromycin Jpn. J. Clin. Pharmacol. Ther. 31 2000 639 648
30. M.V. Varma, K. Sateesh, and R. Panchagnula Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport Mol. Pharm. 2 2005 12 21 (Pubitemid 40314725)
31. M. Verschraagen, C.H. Koks, J.H. Schellens, and J.H. Beijnen P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil Pharmacol. Res. 40 1999 301 306 (Pubitemid 29472055)
32. T. Watanabe, R. Onuki, S. Yamashita, K. Taira, and Y. Sugiyama Construction of a functional transporter analysis system using MDR1 knockdown Caco-2 cells Pharm. Res. 22 2005 1287 1293 (Pubitemid 41176032)
33. L.K. Webster, E.J. Cosson, K.H. Stokes, and M.J. Millward Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice Br. J. Cancer 73 1996 522 524
34. D.M. Woodcock, S. Jefferson, M.E. Linsenmeyer, P.J. Crowther, G.M. Chojnowski, B. Williams, and I. Bertoncello Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs Cancer Res. 50 1990 4199 4203 (Pubitemid 20225651)
35. D.K. Yu The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions J. Clin. Pharmacol. 39 1999 1203 1211 (Pubitemid 30644000)
36. Y. Zhang, X. Guo, E.T. Lin, and L.Z. Benet Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor Drug. Metab. Dispos. 26 1998 360 366 (Pubitemid 28201247)